|
To read the PDF files you will need Adobe Reader.
|
|
|
 |
|
 |
|
March 15, 2011 |
|
Impact of the Tohoku district-off the Pacific Ocean Earthquake |
|
|
|
|
November 13, 2009 |
|
License Agreement for bFGF in Wound Healing Applications in Europe and North America |
|
|
|
|
July 04, 2007 |
|
Licensing Agreement for the Development, Manufacturing and Marketing of Alpha-9 Antibodies |
|
|
|
|
June 19, 2007 |
|
Kaken and Sunstar to sign a License Agreement for Dental Applications of bFGF in North America and Europe |
|
|
|
|
December 20, 2005 |
|
Kaken licenses out Fiblast® Spray in China |
|
|
|
|
March 14, 2005 |
|
Kaken Obtains Worldwide Rights to bFGF |
|
|
|
|
February 23, 2005 |
|
Kaken to launch “GHRP Kaken 100 Injection” for Diagnosis of Growth Hormone Deficiency |
|
|
|
|
July 7, 2004 |
|
Kaken Launches the Benzylamine Anti-tinea Drug Mentax Spray |
|
|
|
|
April 27, 2004 |
|
Kaken Pharmaceutical and Taiyo Yakuhin Enter into an Exclusive Agreement for Marketing of Prink Injection Syringe, an Alprostadil Preparation in Pre-filled Syringe |
|
|
|
|
April 24, 2003 |
|
Kaken Pharmaceutical to Increase Year-end Dividend for the 83rd Fiscal Year Ended March 2003 |
|
|
|
|
April 10, 2003 |
|
7th Journal of Pharmaceutical Science and Technology, Japan Prize for the Most Outstanding Thesis Goes to Kaken Pharmaceutical's Researchers |
|
|
|
|
March 24, 2003 |
|
KAKEN to outsource the West Japan Distribution Center |
|
|
|
|
February 20, 2003 |
|
KAKEN PHARMACEUTICAL CO. and ELITRA PHARMACEUTICALS announce antifungal drug discovery and development collaboration  |
|
|
|
|
December 16, 2002 |
|
GlaxoSmithKline and Kaken Pharmaceutical To co-promote Zyloric® Tablets 50/100 |
|
|
|
|
August 9, 2002 |
|
"Fiblast Spray" to Be Launched in Korea |
|
|
|
|
March 26, 2002 |
|
KAKEN PHARMACEUTICAL Start Operations of Post-marketing Safety Information Management System |
|
|
|
|
February 8, 2002 |
|
Mentax to Be Launched in the US as OTC Drug for Athlete's Foot |
|
|
|
|
December 17, 2001 |
|
Pharmacia and KAKEN Revise Copromotion Agreement for Cytotec, a Drug for NSAID-induced Ulcers |
|
|
|
|
September 7, 2001 |
|
KAKEN Obtains ISO14001 Certificate for Its Shizuoka Site |
|
|
|
|
February 21, 2001 |
|
Launching of ゛MIROL Ophth. Soln. 0.5%", a Long-acting Eye Drop for Glaucoma and Ocular Hypertension |
|
|
|
|
December 14, 2000 |
|
KAKEN PHARMACEUTICAL CO., LTD. and the Institute for Diabetes Discovery, L.L.C. Announce Joint Drug Discovery Program for Insulin Resistance in Type II Diabetes |
|
|
|
|
December 7, 2000 |
|
N.K.Curex and KAKEN to Tie up for Marketing of Diabetic Neuropathy Treatment Aldos |
|
|
|
|
August 3, 2000 |
|
Agreement regarding the sales of Mirol Eye Drop 0.5% with Kyorin Pharmaceutical |
|
|
|
|
February 24, 2000 |
|
Daiichi Pharmaceutical Transfers Manufacturing Rights for Norinyl T28 Contraceptive to KAKEN PHARMACEUTICAL |
|
|
|
|
November 25,1999 |
|
Ebrantil became the first α１-blocker approved for neurogenic dysuria in the world |
|
|
|
|
October 27, 1999 |
|
Toray and KAKEN PHARMACEUTICAL Solidify Relationship through Stock Swap |
|
|
|
|
September 21, 1999 |
|
KAKEN to close Shiga Factory, Transfer Functions to Shizuoka Factory |
|
|
|
|
August 30, 1999 |
|
Launching of Noriyl T28 (Low-dose Oral Contraceptive) |
|
|
|
|
December 16, 1998 |
|
Arthrotec in-licensing agreement with G.D. Searle |
|
|
|
|
February 24, 1997 |
|
Sales Contract With Genzyme Finalized: Antipostoperative Adhesion Agent "Seprafilm" to Be Marketed by KAKEN |
|
|
|
|
November 13,1996 |
|
Antifungal Agent "Mentax" ( Butenafine HCl ) Approved by FDA |
|
|
|
|
July 25,1996 |
|
Application Made for Intractable Skin Ulcer Medication "Fiblast" |
|
|
